Draft Appeals Guidance Does Not Address Industry’s Main Concerns, Says Device Attorney
This article was originally published in The Gray Sheet
Executive Summary
FDA’s new draft guidance explains the various routes to appeal a CDRH decision, but doesn’t do much to reform the appeals process, according to one device attorney.
You may also be interested in...
Draft Guidance Addresses Company Requests For Rationale Of FDA Decisions
The document offers FDA’s interpretation of the terms “substantive summary” and “significant decisions,” both of which appear in new statutory provisions related to the longstanding process for manufacturers to appeal an agency decision.
Regulatory News In Brief
Radiological health post-market offices moving to OIVD. FDA issues global engagement report. More regulatory news.
Regulatory News In Brief
FDA's device center issues a significant draft guidance on the 510(k) program, plus a draft on appeals processes open to sponsors. More end-of-the-year regulatory developments.